{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:20:44Z","timestamp":1790414444488,"version":"4.1.0"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00151","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T04:15:17Z","timestamp":1549512917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis"],"prefix":"10.3389","volume":"10","author":[{"given":"Lotte","family":"Nijhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke G. C.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"van Loosdregt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"B2","first-page":"72","article-title":"Update on treatment of arthritis in children: New treatments, new goals","volume":"64","author":"Lovell","year":"2006","journal-title":"Bull NYU Hosp Jt Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/art.24534","article-title":"Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets","volume":"60","author":"Griffin","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat Rev Rheumatol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0950-3579(98)80018-6","article-title":"Systemic onset juvenile rheumatoid arthritis","volume":"12","author":"Schneider","year":"1998","journal-title":"Baillieres Clin Rheumatol."},{"key":"B6","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","article-title":"Autoimmunity reviews the pathogenesis of oligoarticular\/polyarticular vs systemic juvenile idiopathic arthritis","volume":"10","author":"Lin","year":"2011","journal-title":"Autoimmun Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/art.23291","article-title":"Interleukin-17\u2013producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers","volume":"58","author":"Nistala","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/1529-0131(200004)43:4<765::AID-ANR7>3.0.CO;2-B","article-title":"Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis","volume":"43","author":"Wedderburn","year":"2000","journal-title":"Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/83707","article-title":"X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy","volume":"27","author":"Wildin","year":"2001","journal-title":"Nat Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1182\/blood-2005-07-2800","article-title":"Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network","volume":"107","author":"de Kleer","year":"2006","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.4049\/jimmunol.172.10.6435","article-title":"CD4+CD25bright Regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis","volume":"172","author":"de Kleer","year":"2004","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.coi.2017.10.002","article-title":"Molecular control of regulatory T cell development and function","volume":"49","author":"Kitagawa","year":"2017","journal-title":"Curr Opin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease","volume":"212","author":"Sakaguchi","year":"2006","journal-title":"Immunol Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nrrheum.2012.149","article-title":"T cells out of control-impaired immune regulation in the inflamed joint","volume":"9","author":"Wehrens","year":"2013","journal-title":"Nat Rev Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/rheumatology\/kep028","article-title":"Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis","volume":"48","author":"Nistala","year":"2009","journal-title":"Rheumatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1182\/blood-2010-12-328187","article-title":"Functional human regulatory T cells fail to control autoimmune inflammation due to PKB\/c-akt hyperactivation in effector cells","volume":"118","author":"Wehrens","year":"2011","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/art.37831","article-title":"Editorial: Quality or quantity? unraveling the role of treg cells in rheumatoid arthritis","volume":"65","author":"Prakken","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/rheumatology\/kev101","article-title":"Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis","volume":"54","author":"Bulatovi\u0107 Calasan","year":"2015","journal-title":"Rheumatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/art.39418","article-title":"Self-Sustained resistance to suppression of CD8+ Teff Cells at the site of autoimmune inflammation can be reversed by tumor necrosis factor and interferon-gamma blockade","volume":"68","author":"Petrelli","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.berh.2018.02.003","article-title":"Update on research and clinical translation on specific clinical areas from biology to bedside: unpacking the mysteries of juvenile idiopathic arthritis pathogenesis","volume":"31","author":"van Loosdregt","year":"2017","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.38132","article-title":"Brief report: anti-tumor necrosis factor \u03b1 targets protein kinase B\/c-akt-induced resistance of effector cells to suppression in juvenile idiopathic arthritis","volume":"65","author":"Wehrens","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"Foell","year":"2010","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","article-title":"The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort","volume":"75","author":"Guzman","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/med.20056","article-title":"Targeting histone deacetylase in cancer therapy","volume":"26","author":"Lin","year":"2006","journal-title":"Med Res Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1146\/annurev.bi.46.070177.004435","article-title":"Structure of chromatin","volume":"46","author":"Kornberg","year":"1977","journal-title":"Annu Rev Biochem."},{"key":"B31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0968-0004(90)90053-E","article-title":"Histone H1 and the regulation of transcription of eukaryotic genes","volume":"15","author":"Zlatanova","year":"1990","journal-title":"Trends Biochem Sci."},{"key":"B32","volume-title":"Molecular Biology of the Cell.","author":"Alberts","year":"2002"},{"key":"B33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.molcel.2006.06.017","article-title":"enhanced histone acetylation and transcription: a dynamic perspective","volume":"23","author":"Clayton","year":"2006","journal-title":"Mol Cell."},{"key":"B34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev.biochem.76.052705.162114","article-title":"Functions of site-specific histone acetylation and deacetylation","volume":"76","author":"Shahbazian","year":"2007","journal-title":"Annu Rev Biochem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat Rev Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1128\/MCB.26.8.3106-3113.2006","article-title":"Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation","volume":"26","author":"Nusinzon","year":"2006","journal-title":"Mol Cell Biol."},{"key":"B38","first-page":"151","article-title":"Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines","volume":"2","author":"Glaser","year":"2003","journal-title":"Mol Cancer Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/86507","article-title":"Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes","volume":"7","author":"Kim","year":"2001","journal-title":"Nat Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0304-3835(01)00418-9","article-title":"Paradoxical effects of trichostatin a: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA","volume":"166","author":"Nair","year":"2001","journal-title":"Cancer Lett."},{"key":"B41","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.bbrc.2004.03.066","article-title":"Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition","volume":"317","author":"Tong","year":"2004","journal-title":"Biochem Biophys Res Commun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/BJ20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem J."},{"key":"B43","first-page":"804","article-title":"Abnormal histone modification patterns in lupus CD4+ T cells","volume":"35","author":"Hu","year":"2008","journal-title":"J Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3899\/jrheum.081115","article-title":"Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts","volume":"36","author":"Horiuchi","year":"2009","journal-title":"J Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/art.33382","article-title":"Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients","volume":"64","author":"Gillespie","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.celrep.2015.08.046","article-title":"Inhibition of super-enhancer activity in autoinflammatory site-derived t cells reduces disease-associated gene expression","volume":"12","author":"Peeters","year":"2015","journal-title":"Cell Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1126\/science.1222794","article-title":"Systematic localization of common disease-associated variation in regulatory DNA","volume":"337","author":"Maurano","year":"2012","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","article-title":"Acetylation of non-histone proteins modulates cellular signalling at multiple levels","volume":"41","author":"Spange","year":"2009","journal-title":"Int J Biochem Cell Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.it.2011.04.001","article-title":"Histone deacetylases as regulators of inflammation and immunity","volume":"32","author":"Shakespear","year":"2011","journal-title":"Trends Immunol."},{"key":"B52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1615\/CritRevImmunol.v31.i3.40","article-title":"Function of histone deacetylase inhibitors in inflammation","volume":"31","author":"Grabiec","year":"2011","journal-title":"Crit Rev Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.4049\/jimmunol.0903610","article-title":"Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production","volume":"185","author":"Grausenburger","year":"2010","journal-title":"J Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaut.2017.09.008","article-title":"A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis","volume":"86","author":"Goschl","year":"2018","journal-title":"J Autoimmun"},{"key":"B55","article-title":"Vital Role of CoREST Complex as a master regulator of Foxp3+ T-regulatory cell gene expression and suppressive function","volume":"17","author":"Wang","year":"2017","journal-title":"Am J Transpl."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1182\/blood-2012-07-441949","article-title":"Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice","volume":"121","author":"Dovey","year":"2013","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2012-08-450916","article-title":"Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function","volume":"121","author":"Heideman","year":"2013","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4049\/jimmunol.1502529","article-title":"HDAC3 is required for the downregulation of RORgammat during thymocyte positive selection","volume":"197","author":"Philips","year":"2016","journal-title":"J Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1128\/MCB.00706-15","article-title":"Histone deacetylase 3 is required for efficient T cell development","volume":"35","author":"Stengel","year":"2015","journal-title":"Mol Cell Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4049\/jimmunol.1500435","article-title":"Histone deacetylase 3 is required for T cell maturation","volume":"195","author":"Hsu","year":"2015","journal-title":"J Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1172\/JCI77088","article-title":"FOXP3+ regulatory T cell development and function require histone\/protein deacetylase 3","volume":"125","author":"Wang","year":"2015","journal-title":"J Clin Invest."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/ajt.14749","article-title":"Histone\/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation","volume":"18","author":"Wang","year":"2018","journal-title":"Am J Transl."},{"key":"B63","doi-asserted-by":"publisher","first-page":"17562","DOI":"10.18632\/oncotarget.15077","article-title":"HDAC4 is expressed on multiple T cell lineages but dispensable for their development and function","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"B64","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/14397595.2016.1218595","article-title":"Genome-wide DNA methylation patterns in CD4+ T cells from Chinese Han patients with rheumatoid arthritis","volume":"27","author":"Guo","year":"2017","journal-title":"Mod Rheumatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1002\/ijc.29979","article-title":"HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells","volume":"138","author":"Xiao","year":"2016","journal-title":"Int J Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.4049\/jimmunol.1001179","article-title":"Histone deacetylase 7 regulates cell survival and TCR signaling in CD4\/CD8 double-positive thymocytes","volume":"186","author":"Kasler","year":"2011","journal-title":"J Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1038\/emboj.2012.295","article-title":"Nuclear export of histone deacetylase 7 during thymic selection is required for immune self-tolerance","volume":"31","author":"Kasler","year":"2012","journal-title":"EMBO J."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1128\/MCB.02091-06","article-title":"Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes","volume":"27","author":"Kasler","year":"2007","journal-title":"Mol Cell Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1074-7613(03)00109-2","article-title":"HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis","volume":"18","author":"Dequiedt","year":"2003","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e2321","DOI":"10.1371\/journal.pone.0002321","article-title":"Resistance of Foxp3+ regulatory T cells to Nur77-induced apoptosis promotes allograft survival","volume":"3","author":"Tao","year":"2008","journal-title":"PLoS ONE"},{"key":"B71","doi-asserted-by":"publisher","first-page":"28833","DOI":"10.1074\/jbc.M111.233932","article-title":"Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity","volume":"286","author":"Yan","year":"2011","journal-title":"J Biol Chem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1053\/j.gastro.2009.10.037","article-title":"Inhibition of HDAC9 Increases T regulatory cell function and prevents colitis in Mice","volume":"138","author":"de Zoeten","year":"2010","journal-title":"Gastroenterology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"ra45","DOI":"10.1126\/scisignal.2002873","article-title":"Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms","volume":"5","author":"Beier","year":"2012","journal-title":"Sci Signal"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.7150\/thno.17615","article-title":"HDAC6 regulates IL-17 expression in T lymphocytes: implications for HDAC6-targeted therapies","volume":"7","author":"Yan","year":"2017","journal-title":"Theranostics"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1128\/MCB.05155-11","article-title":"Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells","volume":"31","author":"de Zoeten","year":"2011","journal-title":"Mol Cell Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1021\/jm200773h","article-title":"Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells","volume":"55","author":"Kalin","year":"2012","journal-title":"J Med Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1021\/acsmedchemlett.5b00303","article-title":"Thiol-based potent and selective HDAC6 inhibitors promote tubulin acetylation and t-regulatory cell suppressive function","volume":"6","author":"Segretti","year":"2015","journal-title":"ACS Med Chem Lett."},{"key":"B79","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13075-017-1357-2","article-title":"Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro","volume":"19","author":"Oh","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B80","doi-asserted-by":"crossref","first-page":"54.11","DOI":"10.4049\/jimmunol.200.Supp.54.11","article-title":"HDAC10 Targeting Regulates Foxp3 Promoter, enhances T-regulatory (Treg) function and suppresses autoimmune colitis","volume":"200","author":"Dahiya","year":"2018","journal-title":"J.Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"8626","DOI":"10.1038\/s41598-017-09211-3","article-title":"Histone\/protein deacetylase 11 targeting promotes Foxp3+ Treg function","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep."},{"key":"B82","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/blood-2016-08-731505","article-title":"T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model","volume":"130","author":"Woods","year":"2017","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1136\/ard.2010.148957","article-title":"SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance","volume":"70","author":"Niederer","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.joca.2012.11.017","article-title":"SIRT1, a class III histone deacetylase, regulates TNF-alpha-induced inflammation in human chondrocytes","volume":"21","author":"Moon","year":"2013","journal-title":"Osteoarthr Cartil."},{"key":"B85","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/aps.2011.189","article-title":"Sirt1 overexpression protects murine osteoblasts against TNF-alpha-induced injury in vitro by suppressing the NF-kappaB signaling pathway","volume":"33","author":"Huang","year":"2012","journal-title":"Acta Pharmacol Sin."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1172\/JCI38902","article-title":"The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice","volume":"119","author":"Zhang","year":"2009","journal-title":"J Clin Invest."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1128\/MCB.01206-10","article-title":"Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival","volume":"31","author":"Beier","year":"2011","journal-title":"Mol Cell Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1182\/blood-2009-02-207118","article-title":"Regulation of treg functionality by acetylation-mediated Foxp3 protein stabilization","volume":"115","author":"Van Loosdregt","year":"2010","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.immuni.2016.05.009","article-title":"Histone deacetylase SIRT1 negatively regulates the differentiation of interleukin-9-producing CD4(+) T Cells","volume":"44","author":"Wang","year":"2016","journal-title":"Immunity"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1073\/pnas.0700298104","article-title":"FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression","volume":"104","author":"Li","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/mi.2014.10","article-title":"Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells","volume":"7","author":"Akimova","year":"2014","journal-title":"Mucosal Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1084\/jem.20132378","article-title":"SIRT1 deacetylates RORgammat and enhances Th17 cell generation","volume":"212","author":"Lim","year":"2015","journal-title":"J Exp Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1038\/s41598-017-04263-x","article-title":"Sirtuin 3 deficiency does not alter host defenses against bacterial and fungal infections","volume":"7","author":"Ciarlo","year":"2017","journal-title":"Sci Rep."},{"key":"B94","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B95","first-page":"1471","article-title":"Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment","volume":"20","author":"Weidle","year":"2000","journal-title":"Anticancer Res."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/art.34565","article-title":"Th17 cells are restrained by treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy","author":"McGovern","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"key":"B98","doi-asserted-by":"publisher","first-page":"20436","DOI":"10.1074\/jbc.M000202200","article-title":"Histone deacetylases specifically down-regulate p53-dependent gene activation","volume":"275","author":"Juan","year":"2000","journal-title":"J Biol Chem."},{"key":"B99","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/35042612","article-title":"Deacetylation of p53 modulates its effect on cell growth and apoptosis","volume":"408","author":"Luo","year":"2000","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1093\/emboj\/cdf616","article-title":"MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation","volume":"21","author":"Ito","year":"2002","journal-title":"EMBO J."},{"key":"B101","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0092-8674(01)00527-X","article-title":"hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase","volume":"107","author":"Vaziri","year":"2001","journal-title":"Cell"},{"key":"B102","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.exphem.2016.02.007","article-title":"Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition","volume":"44","author":"Kuo","year":"2016","journal-title":"Exp Hematol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1345\/aph.1R036","article-title":"Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma","volume":"46","author":"Kim","year":"2012","journal-title":"Ann Pharmacother."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/cmi.2012.28","article-title":"SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection","volume":"9","author":"Zhang","year":"2012","journal-title":"Cell Mol Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood-2014-10-605238","article-title":"Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans","volume":"125","author":"Choi","year":"2015","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(13)70512-6","article-title":"Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Choi","year":"2014","journal-title":"Lancet Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clim.2014.01.002","article-title":"Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo","volume":"151","author":"Regna","year":"2014","journal-title":"Clin Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2119\/molmed.2011.00058","article-title":"Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis","volume":"17","author":"Joosten","year":"2011","journal-title":"Mol Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2119\/molmed.2011.00020","article-title":"Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat)","volume":"17","author":"Furlan","year":"2011","journal-title":"Mol Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2119\/molmed.2011.00030","article-title":"HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis","volume":"17","author":"Vojinovic","year":"2011","journal-title":"Mol Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.yexmp.2009.06.003","article-title":"Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis","volume":"87","author":"Saouaf","year":"2009","journal-title":"Exp Mol Pathol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3389\/fimmu.2018.01525","article-title":"Attenuation of Rheumatoid Inflammation by Sodium Butyrate Through Reciprocal Targeting of HDAC2 in Osteoclasts and HDAC8 in T Cells","volume":"9","author":"Kim","year":"2018","journal-title":"Front Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.kint.2015.12.051","article-title":"Targeting Sirtuin-1 prolongs murine renal allograft survival and function","volume":"89","author":"Levine","year":"2016","journal-title":"Kidney Int."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.4049\/jimmunol.0901467","article-title":"Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue","volume":"184","author":"Grabiec","year":"2010","journal-title":"J Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1073\/pnas.052702999","article-title":"The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines","volume":"99","author":"Leoni","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B117","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/SHK.0b013e3181a44c79","article-title":"Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents","volume":"32","author":"Li","year":"2009","journal-title":"Shock"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","article-title":"The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo","volume":"11","author":"Leoni","year":"2005","journal-title":"Mol Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/rheumatology\/keq108","article-title":"Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells","volume":"49","author":"Choo","year":"2010","journal-title":"Rheumatology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/annrheumdis-2015-209064","article-title":"Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes","volume":"76","author":"Angiolilli","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13075-018-1638-4","article-title":"Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation","volume":"20","author":"Angiolilli","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B122","doi-asserted-by":"publisher","first-page":"22211","DOI":"10.1074\/jbc.M110.180224","article-title":"Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells","volume":"286","author":"Huber","year":"2011","journal-title":"J Biol Chem."},{"key":"B123","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1868-7083-4-4","article-title":"The epigenetic effects of butyrate: potential therapeutic implications for clinical practice","volume":"4","author":"Berni Canani","year":"2012","journal-title":"Clin Epigenet."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2485S","DOI":"10.1093\/jn\/133.7.2485S","article-title":"Inhibition of histone deacetylase activity by butyrate","volume":"133","author":"Davie","year":"2003","journal-title":"J Nutr."},{"key":"B125","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/MCO.0b013e32833eebe5","article-title":"Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?","volume":"13","author":"Meijer","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B126","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med."},{"key":"B127","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1520-7560(199905\/06)15:3<181::AID-DMRR31>3.0.CO;2-H","article-title":"A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI)","volume":"15","author":"Visalli","year":"1999","journal-title":"Diabetes Metab Res Rev."},{"key":"B128","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/dmrr.767","article-title":"Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy","volume":"24","author":"Chianelli","year":"2008","journal-title":"Diabetes Metab Res Rev."},{"key":"B129","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2337\/diabetes.47.6.980","article-title":"The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes","volume":"47","author":"Lampeter","year":"1998","journal-title":"Diabetes"},{"key":"B130","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0140-6736(04)15786-3","article-title":"European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes","volume":"363","author":"Gale","year":"2004","journal-title":"Lancet"},{"key":"B131","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2337\/diacare.19.12.1357","article-title":"Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM","volume":"19","author":"Pozzilli","year":"1996","journal-title":"Diabetes Care"},{"key":"B132","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1530\/eje.0.1500719","article-title":"A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX)","volume":"150","author":"Crino","year":"2004","journal-title":"Eur J Endocrinol."},{"key":"B133","first-page":"235","article-title":"Treatment of arthritis by nicotinic acid and nicotinamide","volume":"81","author":"HOFFER","year":"1959","journal-title":"Can Med Assoc J."},{"key":"B134","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1745-7254.2006.00313.x","article-title":"Effect of nicotinamide on newly diagnosed type 1 diabetic children","volume":"27","author":"Kamal","year":"2006","journal-title":"Acta Pharmacol Sin."},{"key":"B135","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.diabres.2005.07.009","article-title":"Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics","volume":"71","author":"Olmos","year":"2006","journal-title":"Diabetes Res Clin Pract."},{"key":"B136","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1464-5491.2006.01921.x","article-title":"The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI)","volume":"23","author":"Pitocco","year":"2006","journal-title":"Diabet Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s001250051536","article-title":"Safety of high-dose nicotinamide: a review","volume":"43","author":"Knip","year":"2000","journal-title":"Diabetologia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T12:43:54Z","timestamp":1694609034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":137,"alternative-id":["10.3389\/fimmu.2019.00151"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00151","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"article-number":"151"}}